EP0938334A4 - Improved method of treating immune cell mediated systemic diseases - Google Patents

Improved method of treating immune cell mediated systemic diseases

Info

Publication number
EP0938334A4
EP0938334A4 EP19970936109 EP97936109A EP0938334A4 EP 0938334 A4 EP0938334 A4 EP 0938334A4 EP 19970936109 EP19970936109 EP 19970936109 EP 97936109 A EP97936109 A EP 97936109A EP 0938334 A4 EP0938334 A4 EP 0938334A4
Authority
EP
Grant status
Application
Patent type
Prior art keywords
improved method
immune cell
cell mediated
systemic diseases
treating immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19970936109
Other languages
German (de)
French (fr)
Other versions
EP0938334A1 (en )
Inventor
Charles Baldwin Davis
Peter John Bugelski
Brian Richard Macdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
EP19970936109 1996-07-26 1997-07-25 Improved method of treating immune cell mediated systemic diseases Withdrawn EP0938334A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US2247296 true 1996-07-26 1996-07-26
US22472P 1996-07-26
PCT/US1997/012600 WO1998004281A1 (en) 1996-07-26 1997-07-25 Improved method of treating immune cell mediated systemic diseases

Publications (2)

Publication Number Publication Date
EP0938334A1 true EP0938334A1 (en) 1999-09-01
EP0938334A4 true true EP0938334A4 (en) 2004-12-15

Family

ID=21809771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19970936109 Withdrawn EP0938334A4 (en) 1996-07-26 1997-07-25 Improved method of treating immune cell mediated systemic diseases

Country Status (3)

Country Link
EP (1) EP0938334A4 (en)
JP (1) JP2000516594A (en)
WO (1) WO1998004281A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
KR20020027311A (en) 1999-05-07 2002-04-13 제넨테크, 인크. Treatment of Autoimmune Diseases with Antagonists Which Bind to B Cell Surface Markers
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ES2524694T3 (en) 2002-10-17 2014-12-11 Genmab A/S CD20 Human Monoclonal Antibodies Against
KR101351122B1 (en) 2003-05-09 2014-01-14 듀크 유니버시티 CD20-Specific Antibodies and Methods of Employing Same
WO2005044859A3 (en) 2003-11-05 2005-08-04 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
CN103203019A (en) 2004-04-09 2013-07-17 艾博特生物技术有限公司 Multiple-variable Dose Regimen For Treating Tnfalpha-related Disorders
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
CN101088014B (en) * 2004-12-23 2012-10-03 弗·哈夫曼-拉罗切有限公司 Detection of a therapeutic antibody in an experimental animal
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2012022682A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
CN104837508A (en) 2012-12-13 2015-08-12 免疫医疗公司 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
WO2015012904A3 (en) 2012-12-13 2015-05-07 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
WO2015130416A9 (en) 2014-02-25 2016-10-06 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009351A1 (en) * 1995-09-06 1997-03-13 Idec Pharmaceuticals Corporation Recombinant anti-cd4 antibodies for human therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126433A (en) * 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009351A1 (en) * 1995-09-06 1997-03-13 Idec Pharmaceuticals Corporation Recombinant anti-cd4 antibodies for human therapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BATA-CSORGO Z ET AL: "Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY. JUL 1995, vol. 105, no. 1 Suppl, July 1995 (1995-07-01), pages 89S - 94S, XP009034211, ISSN: 0022-202X *
EMMRICH F ET AL: "An anti-CD4 antibody for treatment of chronic inflammatory arthritis.", AGENTS AND ACTIONS. SUPPLEMENTS. 1991, vol. 32, 1991, pages 165 - 170, XP001182725, ISSN: 0379-0363 *
GAVETT S H ET AL: "Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. JUN 1994, vol. 10, no. 6, June 1994 (1994-06-01), pages 587 - 593, XP009034204, ISSN: 1044-1549 *
KAINE J ET AL: "RESULTS OF A MULTI-DOSE PROTOCOL 7002 USING AN IMMUNOMODULATING NON-DEPLETING PRIMATIZEDTM ANTI-CD4 MONOCLONAL ANTIBODY IN RHEUMATOID ARTHRITIS (RA)", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 38, no. 9, SUPPL, 21 November 1995 (1995-11-21), pages S185,AN195, XP001095999, ISSN: 0004-3591 *
MORELAND L W ET AL: "TREATING RHEUMATOID ARTHRITIS WITH A NON-DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY", JOURNAL OF INVESTIGATIVE MEDICINE, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, US, vol. 43, no. SUPPL 2, 5 May 1995 (1995-05-05), pages 362A, XP001106168, ISSN: 1081-5589 *
See also references of WO9804281A1 *
THIVOLET J ET AL: "Immunointervention in psoriasis with anti-CD4 antibodies.", INTERNATIONAL JOURNAL OF DERMATOLOGY. MAY 1994, vol. 33, no. 5, May 1994 (1994-05-01), pages 327 - 332, XP009034206, ISSN: 0011-9059 *
YOCUM D E ET AL: "CLINICAL AND IMMUNOPHARMACOLOGIC EFFECTS OF PRIMATIZEDTM IDEC-CE9.1, AN ANTI-CD4 MONOCLONALANTIBODY IN A PHASE I TRIAL IN ACTIVE RHEUMATOID ARTHRITIS", JOURNAL OF INVESTIGATIVE MEDICINE, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, US, vol. 43, no. SUPPL 2, April 1995 (1995-04-01), pages 253A, XP001095992, ISSN: 1081-5589 *

Also Published As

Publication number Publication date Type
WO1998004281A1 (en) 1998-02-05 application
EP0938334A1 (en) 1999-09-01 application
JP2000516594A (en) 2000-12-12 application

Similar Documents

Publication Publication Date Title
EP0314863A3 (en) Method of treatment for non-specific inflammation
US5827889A (en) Anal fissure treatment preparation and method
GB2298713B (en) Method and composition
JPS63194667A (en) Plasma treatment method and product thereof
JPS6338536A (en) Plasma arc heating method and apparatus
JPH0850828K1 (en) Process and apparatus for covering conductors using longitudinal type cooling pool
GB2317496B (en) Chipshooter manufacturing system and method of operation
GB2326372B (en) Moulding method and apparatus
JPS62263645A (en) Construction of electric contact and method of forming the same
EP0704492A3 (en) Molding method of composite
GB2255262B (en) Electric heater and method of making same
GB2333527B (en) Therapeutic gene
GB9723149D0 (en) Method and means of protection
GB9519661D0 (en) Fatty acid treatment
GB9515185D0 (en) Fatty acid treatment
GB9725593D0 (en) Method of ornamentation
GB9710439D0 (en) Method of distinguishing and separating materials
GB9523141D0 (en) Improvements in or relating to electric motors and centrifugal apparatus
GB9402347D0 (en) Plasma treatment process
GB9619299D0 (en) Separation method
GB9410639D0 (en) Method of improving fertilization
GB9524221D0 (en) Fractionating method and apparatus
GB9412832D0 (en) Method of decoration
GB9620170D0 (en) Cure for eczema and other mild skin diseases
KR182366B1 (en) Electrical discharging method and device

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

17P Request for examination filed

Effective date: 19990215

A4 Despatch of supplementary search report

Effective date: 20041022

18D Deemed to be withdrawn

Effective date: 20050111